Description
Blarcamesine (AVex-73;AE-37) is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcamesine ameliorates neurologic impairments in a mouse model of Rett syndrome.
Product information
CAS Number: 195615-83-9
Molecular Weight: 281.39
Formula: C19H23NO
Chemical Name: [(2,2-diphenyloxolan-3-yl)methyl]dimethylamine
Smiles: CN(C)CC1CCOC1(C1C=CC=CC=1)C1C=CC=CC=1
InChiKey: BOTHKNZTGGXFEQ-UHFFFAOYSA-N
InChi: InChI=1S/C19H23NO/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17/h3-12,18H,13-15H2,1-2H3
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: Soluble in DMSO
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vivo:
Blarcamesine (10 mg/kg, 30 mg/kg; p.o.; daily; for 6.5 weeks) ameliorates motor deficits in Mecp2 HET mice with chronic administration. Blarcamesine ameliorates acoustic startle deficit in Mecp2 HET mice. Blarcamesine reverses deficits in visual acuity in older Mecp2 HET mice using the optokinetic response. Blarcamesine produces minimal effects on body weight gain in Mecp2 HET mice.
References:
- Walter E Kaufmann, et al. ANAVEX®2-73 (Blarcamesine), a Sigma-1 Receptor Agonist, Ameliorates Neurologic Impairments in a Mouse Model of Rett Syndrome. Pharmacol Biochem Behav . 2019 Dec;187:172796.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.